Mutant OPAA Enzyme Catalytic Efficiency on GP
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current organophosphorus acid anhydrolases have limited catalytic activity against the highly toxic chemical nerve agent GP, making them marginally useful for decontamination and medical countermeasures.
Innovation Solution
A non-wild-type organophosphorus acid anhydrolase with specific mutations at positions 212, 342, and 215, such as Y212F, V342L, and I215K, significantly enhances catalytic efficiency for GP degradation, offering a more effective decontamination and treatment option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type OPAA enzyme is used, then the enzyme can degrade various chemical nerve agents, but the catalytic activity against GP is limited
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions at positions 212, 342, and 215 in the OPAA enzyme sequence. These localized changes modify the enzyme's active site or binding region to specifically enhance GP degradation capability while preserving overall enzyme function. The mutations create a specialized local structure that optimizes interaction with GP substrate.
Solution Approach 2:
The patent employs parameter changes by altering the amino acid sequence parameters at specific positions (212, 342, 215) to optimize enzyme performance. The substitutions (e.g., Y212F, V342L, I215K) change the physical and chemical properties of the enzyme, such as hydrophobicity, steric configuration, or electrostatic interactions, thereby enhancing catalytic efficiency toward GP.
2Productivity
If mutant OPAA with substitutions at positions 212, 342, and 215 is created, then catalytic efficiency on GP increases approximately 4 times, but the enzyme sequence becomes non-wild-type
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at positions 212, 342, and 215 to optimize catalytic efficiency. The specific substitutions (Y212F, V342L, I215K) alter local chemical environment and enzyme-substrate interaction parameters, resulting in 4-fold increase in GP degradation rate while maintaining enzyme structural integrity.
Solution Approach 2:
The mutations introduce local quality changes at specific positions in the enzyme sequence, creating optimized local regions that enhance GP binding or catalysis without requiring global sequence changes. This localized optimization achieves high productivity while minimizing overall sequence alteration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated enzyme demonstrates approximately 4 times greater catalytic efficiency on GP compared to the wild-type enzyme, providing a superior decontamination and treatment solution for GP poisoning.
Implementation Method 1
a class of enzymes known as organophosphorus acid ('OPA') anhydrolases ('OPAA') (EC 3.1.8.2) can catalyze the hydrolysis of a variety of OP compounds
Implementation Method 2
The catalytic efficiency of this mutant on GP is approximately 4 times greater that than of the wild-type enzyme
Data Source
AI summary
The invention is directed toward mutant, non-wild-type organophosphorus acid anhydrolase enzymes having three site mutations, methods of production, and methods of use to effectively degrade toxic organophosphorus compounds, most preferably GP (2,2′-dimethylcyclopentyl methylphosphonofluoridate).